Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. Issue 1 (December 2016)

• Record Type: Journal Article
• Authors: Bourgeois-Daigneault, Marie-Claude; St-Germain, Lauren; Roy, Dominic; Pelin, Adrian; Aitken, Amelia; Arulanandam, Rozanne; Falls, Theresa; Garcia, Vanessa; Diallo, Jean-Simon; Bell, John
• Is Part Of: Breast cancer research. Volume 18:Issue 1(2016)
• Page Start: 1
• Page End: 10
• Publication Date: 2016-12
• Subjects: Breast Cancer -- Triple-negative breast cancer -- TNBC -- Oncolytic virus -- Rhabdovirus Maraba-MG1 -- Paclitaxel -- Viral Sensitizer -- Combination therapy; Breast -- Cancer -- Periodicals; 616.99449
• DOI: 10.1186/s13058-016-0744-y
• Languages: English
• ISSNs: 1465-542X

Abstract

Abstract Background Breast cancer is the most common malignant disease amongst Western women. The lack of treatment options for patients with chemotherapy-resistant or recurrent cancers is pushing the field toward the rapid development of novel therapies. The use of oncolytic viruses is a promising approach for the treatment of disseminated diseases like breast cancer, with the first candidate recently approved by the Food and Drug Administration for use in patients. In this report, we demonstrate the compatibility of oncolytic virotherapy and chemotherapy using various murine breast cancer models. This one-two punch has been explored in the past by several groups with different viruses and drugs and was shown to be a successful approach. Our strategy is to combine Paclitaxel, one of the most common drugs used to treat patients with breast cancer, and the oncolytic Rhabdovirus Maraba-MG1, a clinical trial candidate in a study currently recruiting patients with late-stage metastatic cancer. Methods We used the EMT6, 4 T1 and E0771 murine breast cancer models to evaluate in vitro and in vivo the effects of co-treatment with MG1 and Paclitaxel. Treatment-induced cytotoxicity was assessed and plaque assays, flow cytometry, microscopy and immunocytochemistry analysis were performed to quantify virus production and transgene expression. Orthotopically implanted tumors were measured during and after treatment to evaluate efficacy and Kaplan-Meier survival curves were generated. Results Our data demonstrate not only the compatibility of the treatments, but also their synergistic cytopathic activity. With Paclitaxel, EMT6 and 4 T1 tumors demonstrated increased virus production both in vitro and in vivo. Our results also show that Paclitaxel does not impair the safety profile of the virus treatment. Importantly, when combined, MG1 and the drug controlled tumor growth and prolonged survival. Conclusions The combination of MG1 and Paclitaxel improved efficacy in all of the breast cancer models we tested and thus is a promising alternative approach for the treatment of patients with refractory breast cancer. Our strategy has potential for rapid translation to the clinic, given the current clinical status of both agents.